Current concepts in antimicrobial therapy against resistant gram-negative organisms: Extended-spectrum β-lactamase-producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa

Mayo Clinic Proceedings

Volumn 86, Issue 3, 2011, Pages 250-259

  Kanj, Souha S ^a   Kanafani, Zeina A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; BETA LACTAMASE; BIAPENEM; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; CEPHAMYCIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; FROPENEM; IMIPENEM; MEROPENEM; NITROFURANTOIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; QUINOLONE DERIVATIVE; RIFAMPICIN; SULBACTAM; TAZOBACTAM; TEMOCILLIN; TIGECYCLINE; TOMOPENEM; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; INFECTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; SKIN INFECTION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 79952420498     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0674     Document Type: Conference Paper

References (107)

1. Peterson LR. Bad bugs, no drugs: no ESCAPE revisited. Clin Infect Dis. 2009;49:992-993.
2. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289:321-331.
3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-1233.
4. Page MG. Extended-spectrum β-lactamases: structure and kinetic mechanism. Clin Microbiol Infect. 2008;14(suppl 1):63-74. (Pubitemid 350269187)
5. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev. 2009;22:161-182.
6. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
7. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440-458.
8. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother. 2005;49:3018-3020.
9. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12:1209-1213.
10. Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8:71-93.
11. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N Engl J Med. 2009;360:439-443.
12. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300:371-379.
13. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006;58:205-210.
14. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007;60:1018-1029. (Pubitemid 47617749)
15. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1-14. (Pubitemid 38040170)
16. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59:165-174. (Pubitemid 47072053)
17. Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682-690.
18. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151-1161. (Pubitemid 32230996)
19. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430-1435. (Pubitemid 40973427)
20. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother. 2005;49:4423-4424. (Pubitemid 41401006)
21. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother. 2007;51:763-765. (Pubitemid 46185304)
22. Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid- mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50:2880-2882. (Pubitemid 44198721)
23. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
24. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-166. (Pubitemid 351249250)
25. Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 2004;38:243-251. (Pubitemid 38113033)
26. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis. 2004;39:31-37. (Pubitemid 38879546)
27. Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum β-lactamase-producing and multidrug-resistant gram-negative bacteraemia. Ann Acad Med Singapore. 2008;37:831-834.
28. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis. 2009;49:291-298.
29. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62:895-904.
30. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10:13-21.
31. Freire AT, Melnyk V, Kim MJ, et al; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68:140-151.
32. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrob Agents Chemother. 1994;38:767-772. (Pubitemid 24114016)
33. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897-1902.
34. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect. 2008;14(suppl 1):181-184. (Pubitemid 350269200)
35. Gavin PJ, Suseno MT, Thomson RB Jr, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006;50:2244-2247. (Pubitemid 43807556)
36. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001;45:3548-3554. (Pubitemid 33107876)
37. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis. 2006;43:1407-1414. (Pubitemid 44845640)
38. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442-3447. (Pubitemid 37345702)
39. Parchuri S, Mohan S, Cunha BA. Extended spectrum β-lactamase- producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B. Heart Lung. 2005;34:360-363. (Pubitemid 41266987)
40. Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis. 1999;28:1134-1138. (Pubitemid 29203552)
41. Galani I, Kontopidou F, Souli M, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents. 2008;31:434-439.
42. Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother. 1994;34:853-858.
43. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008;27:439-443. (Pubitemid 351713066)
44. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43-50.
45. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010;29:127-142.
46. Glupczynski Y, Huang TD, Berhin C, et al. In vitro activity of temocillin against prevalent extended-spectrum β-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis. 2007;26:777-783.
47. Nicolle LE, Mulvey MR. Successful treatment of CTX-M ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis. 2007;39:748-749. (Pubitemid 47180483)
48. Jia B, Lu P, Huang W, et al. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Chemotherapy. 2010;56:285-290.
49. Mushtaq S, Hope R, Warner M, Livermore DM. Activity of faropenem against cephalosporin-resistant Enterobacteriaceae. J Antimicrob Chemother. 2007;59:1025-1030. (Pubitemid 47073380)
50. Koga T, Abe T, Inoue H, et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother. 2005;49:3239-3250.
51. Garau J. Other antimicrobials of interest in the era of extended-spectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008;14(suppl 1):198-202. (Pubitemid 350269204)
52. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128-132. (Pubitemid 41418346)
53. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2008;52:570-573. (Pubitemid 351170830)
54. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119-1125.
55. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46:567-570. (Pubitemid 351263497)
56. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents. 2007;30:525-529. (Pubitemid 350064465)
57. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J Hosp Infect. 2010;76:70-73.
58. Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54:526-529.
59. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother. 2010;54:2732-2734.
60. Melchers R, Mavridou E, Van Mil A, Motyl MR, Mouton JW. In vitro activity of imipenem alone and in combination with MK-7655: a new β-lactamase inhibitor [poster F1-2138]. Poster presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010.
61. Livermore DM. Spectrum and potential of NXL104 as a β-lactamase inhibitor [poster 1849]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010.
62. Sheri A, Pagadala SR, Young K, et al. Optimization of a carbapenem/β-lactamase inhibitor combination against highly resistant gram-negative microorganisms [poster F1-1496]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010.
63. Jacobs MR, Bajaksouzian S, Butler MM, et al. Activity of novel bis-indole agents against carbapenemase-producing Klebsiella pneumoniae [poster F1-1632]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010.
64. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010;54:3717-3722.
65. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordmann P. Efficacy of β-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-β-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002;46:2032-2034. (Pubitemid 34535240)
66. Gimeno C, Canton R, Garcia A, Gobernado M. Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study [in Spanish]. Rev Esp Quimioter. 2010;23:144-152.
67. Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother. 2008;52:4388-4399.
68. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004;48:3086-3092. (Pubitemid 38989178)
69. Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2192-2196. (Pubitemid 43807542)
70. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007;33:1162-1167. (Pubitemid 47036903)
71. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154-e160.
72. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
73. Daikos GL, Skiada A, Pavleas J, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother. 2010;22:175-178.
74. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-199.
75. Korvick JA, Peacock JE Jr, Muder RR, Wheeler RR, Yu VL. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother. 1992;36:620-625.
76. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540-546. (Pubitemid 19274758)
77. Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003;47:2756-2764. (Pubitemid 37040244)
78. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials [published correction appears in BMJ. 2004;328(7444):884]. BMJ. 2004;328:668.
79. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? a meta-analysis. Lancet Infect Dis. 2004;4:519-527. (Pubitemid 39077923)
80. Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with β-lactams and amikacin. J Antimicrob Chemother. 2005;56:353-359.
81. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis. 2005;40(suppl 2):S105-S114. (Pubitemid 40270208)
82. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic- resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379-1382. (Pubitemid 29259329)
83. Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of β-lactam resistance. J Clin Microbiol. 2001;39:2072-2078. (Pubitemid 32531461)
84. Dundar D, Otkun M. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med J. 2010;51:111-116.
85. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 2002;50:1045-1049. (Pubitemid 36032829)
86. Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med. 1983;101:896-902. (Pubitemid 13100684)
87. Urena MT, Barasoain I, Espinosa M, Garcia E, Portoles A. Evaluation of different antibiotic actions combined with rifampicin: in vitro synergism against Pseudomonas and Proteus. Chemotherapy. 1975;21:82-89.
88. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47:905-909. (Pubitemid 36254214)
89. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2002;46:1105-1107. (Pubitemid 34260359)
90. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents. 2006;27:224-228.
91. Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother. 2010;65:82-90.
92. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML; The Endotracheal Tobramycin Study Group. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother. 1990;34:269-272.
93. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet. 2001;358:983-984. (Pubitemid 32913526)
94. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121:55-63. (Pubitemid 34114228)
95. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005;41:754-757. (Pubitemid 41170367)
96. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Int J Antimicrob Agents. 2001;17:177-188. (Pubitemid 32229895)
97. Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun. 2009;77:1083-1090.
98. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51:826-830.
99. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+ NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65(11):2376-2381.
100. Venkatesan AM, Agarwal A, Abe T, et al. Novel imidazole substituted 6-methylidene-penems as broad spectrum β-lactamase inhibitors. Bioorg Med Chem. 2004;12:5807-5817. (Pubitemid 39388180)
101. Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol. 2009;9:558-565.
102. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44:357-363. (Pubitemid 46147617)
103. Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion β-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010;44:929-935.
104. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116-1123. (Pubitemid 37174443)
105. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med. 2008;36:1089-1096. (Pubitemid 351482655)
106. Malafaia O, Umeh O, Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [poster L-1564b]. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA; September 27-30, 2006.
107. Bulik CC, Nicolau DP. In vivo efficacy of 1g human simulated prolonged infusion doripenem (DOR) against carbapenemase producing Klebsiella pneumoniae (KPC) [poster A1-014]. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; September 12-15, 2010.